{
  "CitationSubset": [],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "28765323",
  "DateCompleted": {
    "Year": "2019",
    "Month": "07",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2017",
        "Month": "08",
        "Day": "01"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1158/1078-0432.CCR-17-1117"
    ],
    "Journal": {
      "ISSN": "1557-3265",
      "JournalIssue": {
        "Volume": "24",
        "Issue": "2",
        "PubDate": {
          "Year": "2018",
          "Month": "Jan",
          "Day": "15"
        }
      },
      "Title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "ISOAbbreviation": "Clin Cancer Res"
    },
    "ArticleTitle": "Tumor-Treating Fields: A Fourth Modality in Cancer Treatment.",
    "Pagination": {
      "StartPage": "266",
      "EndPage": "275",
      "MedlinePgn": "266-275"
    },
    "Abstract": {
      "AbstractText": [
        "Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. <i>Clin Cancer Res; 24(2); 266-75. \u00a92017 AACR</i>."
      ],
      "CopyrightInformation": "\u00a92017 American Association for Cancer Research."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Washington, Department of Internal Medicine, Seattle, Washington. ejmun@uw.edu."
          }
        ],
        "LastName": "Mun",
        "ForeName": "Elijah J",
        "Initials": "EJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Translational Genomics Research Institute (TGen), University of Arizona Cancer Center, Tucson, Arizona."
          }
        ],
        "LastName": "Babiker",
        "ForeName": "Hani M",
        "Initials": "HM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Novocure Ltd., Topaz Building, MATAM Center, Haifa, Israel."
          }
        ],
        "LastName": "Weinberg",
        "ForeName": "Uri",
        "Initials": "U"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Novocure Ltd., Topaz Building, MATAM Center, Haifa, Israel."
          }
        ],
        "LastName": "Kirson",
        "ForeName": "Eilon D",
        "Initials": "ED"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Virginia G. Piper Cancer Center Clinical Trials, HonorHealth Research Institute, Scottsdale, Arizona."
          },
          {
            "Identifier": [],
            "Affiliation": "Translational Genomics Research Institute (TGen), Clinical Translational Research Division, Phoenix, Arizona."
          }
        ],
        "LastName": "Von Hoff",
        "ForeName": "Daniel D",
        "Initials": "DD"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Clin Cancer Res",
    "NlmUniqueID": "9502500",
    "ISSNLinking": "1078-0432"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "adverse effects",
        "instrumentation",
        "methods"
      ],
      "DescriptorName": "Combined Modality Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "mortality",
        "pathology",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}